Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

Alvotech and LOTTE Biologics announced a long-term strategic manufacturing partnership under which LOTTE will produce drug substance for multiple antibody biosimilars at its Syracuse, New York facility for global supply. The Syracuse site offers 40,000 liters of bioreactor capacity, recently completed an unannounced FDA inspection with zero observations, and gives Alvotech a US manufacturing footprint to complement its in-house capabilities. Alvotech CEO Lisa Graver said the expanded network provides capacity to meet demand for the pipeline for the next ten years.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.